| Using genomcs to develop new antibiotics and vaccines could help prepare for potential bioterrorist actions|
Genomic data will continue rapidly accumulating as sequencing techniques and computing power keep advancing, noted J. Craig Venter, the two-day seminar's cochairman and chief scientific officer of Celera Genomics Corp., of Rockville, Md. Venter noted that since he and a team of scientists at The Institute for Genomic Research (TIGR), in Rockville, Md., finished the first genome, Haemophilus influenzae, in 1995,1 about 20 genomes have been completed, 80 more microbial...
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?